EICHORCondition: Light Chain (AL) Amyloidosis · Sponsor: Nexcella Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Open-label Phase 1b Dose Escalation/Dose Expansion study exploring the safety and efficacy of NXC-201 in patients with relapsed or refractory light chain amyloidosis (AL).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Sutter Health Alta Bates | Berkeley, California, United States | — |
| City of Hope | Duarte, California, United States | — |
| University of California Los Angeles | Los Angeles, California, United States | — |
| University of California Davis Medical Center | Sacramento, California, United States | — |
| Stanford University | Stanford, California, United States | — |
| Winship Cancer Institute, Emory University | Atlanta, Georgia, United States | — |
| The University of Kansas Cancer Center | Fairway, Kansas, United States | — |
| Tufts Medical Center | Boston, Massachusetts, United States | — |
| Boston University Medical Center | Boston, Massachusetts, United States | — |
| Barbara Ann Karmanos Cancer Institute | Detroit, Michigan, United States | — |
| Masonic Cancer Center, University of Minnesota | Minneapolis, Minnesota, United States | — |
| Washington University Siteman Cancer Center | St Louis, Missouri, United States | — |
+ 6 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06097832